Coronado Industries Earns Favorable Reception From European Parliament.Business Editors FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--Feb. 29, 2000 Coronado Industries, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). , today announced that its presentation earlier this week to the European Parliament European Parliament, a branch of the governing body of the European Union (EU). It convenes on a monthly basis in Strasbourg, France; most meetings of the separate parliamentary committees are held in Brussels, Belgium, and its Secretariat is located in Luxembourg. in Brussels, Belgium about Pneumatic Trabeculoplasty (PNT PNT Point PNT Paint (MacPaint graphic file format) PNT Patient PNT Pentagon (Washington, DC; US DoD) PNT Positioning, Navigation and Timing PNT Prime Number Theorem PNT Phenytoin (tm)) received a highly favorable response. Gary Smith, president of Coronado Industries, and Dr. Leo Leo, in astronomy Leo [Lat.,=the lion], northern constellation lying S of Ursa Major and on the ecliptic (apparent path of the sun through the heavens) between Cancer and Virgo; it is one of the constellations of the zodiac. Bores, Medical Director of the Company's wholly-owned subsidiary Ophthalmic International, accepted a special invitation from the Parliament to present over five years' results of PNT device and treatment clinical trials. The findings are now being distributed to the Ministers of Health of the Parliament's member countries, to support the inclusion of PNT as an accepted glaucoma treatment under their National Health Systems. Gary Smith commented, "The favorable response we received in Brussels is indicative of the European ophthalmologic community's interest in PNT as a valid glaucoma treatment. The device has already been approved for a CE Mark, which allows us to export it to Europe." Smith continued, "The opportunity to present our results to the Parliament brings us a giant step closer to distributing our product in Europe. It also supports our application for listing on the German stock exchange, an event which we expect to occur in the very near future." Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Opthalmic International, has developed and tested the patented procedure Pneumatic Trabeculoplasty (PNT(tm)), a non-invasive, highly effective, and low-cost alternative to traditional treatments. Currently, the Company's pneumatic suction device and treatment are available throughout the European marketplace. Coronado awaits FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval, upon which it will license its patented treatment procedure and equipment in the United States. Forward-looking statements in this release are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion